New MRI scan could reveal Cancer's true aggressiveness

NCT ID NCT05599048

Recruiting now Diagnosis Sponsor: Robert Bok, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is to see if this imaging method can predict treatment success better than current scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hyperpolarized 13C-pyruvate and 13C,15N-urea (special contrast agents for MRI)
What this could lead to: If successful, this could lead to a new way to quickly see if a cancer treatment is working, without needing a biopsy.
What could go wrong: This is an early-phase study with only 65 people, so the results may not apply to everyone. The special MRI scan is still experimental and may not be better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.